Assessment of the therapeutic activity of a combination of almitrine and raubasine on functional rehabilitation following ischaemic stroke

Current Medical Research and Opinion

Volumn 20, Issue 3, 2004, Pages 409-415

  Li, Shunwei ^a,b   Long, Jie ^a   Ma, Zhizhong ^a   Xu, Zhongbao ^a   Li, Jing ^a   Zhang, Zhuo ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Duxil (almitrine + raubasine); Ischaemic stroke; Stroke

Indexed keywords

AJMALICINE PLUS ALMITRINE; ALANINE AMINOTRANSFERASE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; FIBRINOGEN; PLACEBO;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BRAIN FUNCTION; BRAIN OXYGEN CONSUMPTION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEART RATE; HUMAN; INSOMNIA; LABORATORY TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC EXAMINATION; OUTCOMES RESEARCH; OXYGEN SUPPLY; PARAMETER; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; STROKE; TABLET;

AGED; ALMITRINE; CEREBROVASCULAR ACCIDENT; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; RECOVERY OF FUNCTION; TREATMENT OUTCOME; YOHIMBINE;

EID: 1542510893     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125003080     Document Type: Article

References (14)

1. Uemura K, Pisa Z. Trends in cardiovascular disease mortality in industrialized countries since 1950. World Health Stat Q 1988;41:155-78
2. Benzi G. Pharmacological features of an almitrine-raubasine combination. Eur Neurol 1998;39(Suppl):31-8
3. Charpenter J. The fundamental stage: the pharmacological action of Duxil. Praticien 1980;372:15-21
4. Chan P, Li Y, Zheng Z. Neurologic and histologic evaluation of almitrine + raubasine (Duxil) in middle cerebral artery occlusion in cats. Eur J Pharmacol 1993;231:175-82
5. Guez D. Evaluation of acute and chronic cerebral ischaemia in human by positron and single photon emission tomography. Application to the study of Duxil. Rev Med Intern 1988;91(Suppl):33-9
6. Allain H, Benture-Ferrrer D. Clinical efficacy of almitrine-raubasine. Eur Neurol 1998;39:39-44
7. Grel P, Menard AM. Therapeutic activity of Duxil in intellectual and behavioural disorders associated with chronic cerebral insufficiency. Double blind controlled trial against placebo. Psychol Med. 1984;16:181-9
8. Pardo A. Therapeutic activity of Duxil in intellectual and behavioural disorders in chronic cerebral impairment. Double blind placebo controlled trial using psychometric tests. J Int Med 1986;73:14-20
9. Saletu B, Grunberger J, Linzmayer L, Anderer P. Double blind placebo controlled quantitative EEG and psychometric studies in the elderly on vigilance. Promoting effects of almitrine-raubasine combination. Arch Gerontol Geriatr 1988;7:93-110
10. Bailly A, Roux C. Etude comparative contre placebo de l'action de Duxil dans l'insuffisance circulatoire cerebrale du sujet age. CR Ther Pharmacol Clin 1982;1:19-27
11. Le Poncin M, Chouckroun E. Clinical and psychometric evaluation of the effects of Duxil on cognitive disorders of the elderly. J Neurol 1988;235(Suppl):S56
12. Rapisarda V, Azzaro E, Fichera G. Evaluation psychometrique des effets de l'association almitrine-raubasine sur l'affaiblissement intellectuel du sujet age. Essai controle a double insu contre placebo. Presse Med 1987;16:1163-6
13. Tsai N, Gao ZX. Validity of Hasegawa's Dementia Scale for screening dementia among aged Chinese. Int Psychogeriatr 1989;1(2):145-52
14. Poitrenaud J, Laurent B, Sebban C. Memory disorders in 8037 elderly patients with age-associated memory impairment: multicenter trial with a 6-month follow-up under almitrine-raubasine. Eur Neurol 1995;35(Suppl):43-6